MDM-2/p53 MDM2 Inhibitor

MDM-2/p53 MDM2 Inhibitors (58):

Cat. No.	Product Name	Effect	Purity

HY-128842

PROTAC MDM2 Degrader-3	MDM2 Inhibitor
PROTAC MDM2 Degrader-3 is a MDM2 degrader based on PROTAC technology. PROTAC MDM2 Degrader-3 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.

HY-16999

RO8994	MDM2 Inhibitor	99.62%
RO8994 (Compound 4) is an orally active, highly potent and selective spiroindolinone p53-MDM2 inhibitor with an IC₅₀ value of 5 nM (HTRF binding assays) and 20 nM (MTT proliferation assays). RO8994 induces up-regulation of p53 expression and Apoptosis in wild-type p53 cancer cells. RO8994 also inhibits tumor growth in the tumor xenograft model.

HY-128841

PROTAC MDM2 Degrader-2	MDM2 Inhibitor
PROTAC MDM2 Degrader-2 is a MDM2 degrader based on PROTAC technology. PROTAC MDM2 Degrader-2 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase (CN108610333A).

HY-16664

SJ-172550	MDM2 Inhibitor	99.95%
SJ-172550 is a small molecule inhibitor of MDMX; competes for the wild type p53 peptide binding to MDMX with an EC₅₀ of 5 μM.

HY-130684

MDM2-IN-1	MDM2 Inhibitor	98.02%
MDM2-IN-1 (Compound 30) is a synthetic MDM2-p53 interaction (MDM2) inhibitor and contains the trans (D-)configuration.

HY-120086

RO-5963	MDM2 Inhibitor	99.97%
RO-5963 is a dual p53-MDM2 and p53-MDMX inhibitor with IC₅₀s of ~17 nM and ~24 nM, respectively.

HY-101266B

Milademetan tosylate hydrate	MDM2 Inhibitor	98.89%
Milademetan (DS-3032) tosylate hydrate is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) tosylate hydrate induces G1 cell cycle arrest, senescence and apoptosis.

HY-100383

BH3I-1	MDM2 Inhibitor	≥98.0%
BH3I-1 is a Bcl-2 family antagonist, which inhibits the binding of the Bak BH3 peptide to Bcl-xL with a K_i of 2.4±0.2 μM in FP assay. BH3I-1 has a K_d of 5.3 μM against the p53/MDM2 pair.

HY-U00442

CTX1	MDM2 Inhibitor
CTX1 is a p53 activator that overcomes HdmX-mediated p53 repression. CTX1 exhibits potent anti-cancer activity in a mouse acute myeloid leukemia (AML) model system.

HY-128840

PROTAC MDM2 Degrader-1	MDM2 Inhibitor	98.11%
PROTAC MDM2 Degrader-1 (Compound 15a) is a MDM2 PROTAC degrader. The structures of both Linker ends of PROTAC MDM2 Degrader-1 are MDM2 ligands. PROTAC MDM2 Degrader-1 can not only block the binding of p53-MDM2, but also degrade the target MDM2 protein by utilizing the function of the E3 ligase of MDM2 itself, thus exerting an anti-tumor effect. (Pink: MDM2 ligand 2 (HY-128836); Black: Linker (HY-128844); Blue: E3 ligase Ligand 15 (HY-128836))

HY-70027A

p53 and MDM2 proteins-interaction-inhibitor dihydrochloride	MDM2 Inhibitor	99.56%
p53 and MDM2 proteins-interaction-inhibitor dihydrochloride is an inhibitor of the interaction between p53 and MDM2 proteins.

HY-12287

YH239-EE	MDM2 Inhibitor	98.28%
YH239-EE, ethyl ester of the free carboxylic acid compound YH239, is a potent p53-MDM2 antagonizing and apoptosis-inducing agent.

HY-108640A

HLI373 dihydrochloride	MDM2 Inhibitor	≥98.0%
HLI373 dihydrochloride is an efficacious Hdm2 inhibitor. HLI373 dihydrochloride inhibits the ubiquitin ligase activity of Hdm2. HLI373 dihydrochloride is effective in inducing apoptosis of several tumor cells that are sensitive to DNA-damaging agents. Antimalarial activity.

HY-15954B

NVP-CGM097 sulfate	MDM2 Inhibitor	98.82%
NVP-CGM097 sulfate is a potent and selective MDM2 inhibitor with IC₅₀ of 1.7±0.1 nM for hMDM2.

HY-70027

p53 and MDM2 proteins-interaction-inhibitor (chiral)	MDM2 Inhibitor	98.13%
p53 and MDM2 proteins-interaction-inhibitor (chiral) (Compound 32) is an inhibitor of the interaction between p53 and MDM2 proteins.

HY-112816A

MA242 free base	MDM2 Inhibitor
MA242 free base is a specific dual inhibitor of MDM2 and NFAT1. MA242 free base directly binds both MDM2 and NFAT1 with high affinity, induces their protein degradation, and inhibits NFAT1-mediated transcription of MDM2. MA242 free base induces apoptosis in pancreatic cancer cell lines regardless of p53 status.

HY-141584

ATSP-7041	MDM2 Inhibitor
ATSP-7041, a selective dual peptide inhibitor of MDM2 and MDMX, effectively reactivates the p53 tumor suppressor pathway in a mechanism-dependent manner in p53-positive cancers.

HY-101266A

Milademetan tosylate	MDM2 Inhibitor
Milademetan tosylate is the tosylate salt form of Milademetan (HY-101266). Milademetan tosylate is an orally active inhibitor for MDM2. Milademetan tosylate arrests the cell cycle at G1 pahse, induces the apoptosis Milademetan tosylate restores the p53 activity by targeting the p53-MDM2 interaction, and exhibits anticancer activity against Merkel cell carcinoma (MCC).

HY-112816

MA242	MDM2 Inhibitor
MA242 is a specific dual inhibitor of MDM2 and NFAT1. MA242 directly binds both MDM2 and NFAT1 with high affinity, induces their protein degradation, and inhibits NFAT1-mediated transcription of MDM2. MA242 induces apoptosis in pancreatic cancer cell lines regardless of p53 status.

HY-100765

BI-0252	MDM2 Inhibitor
BI-0252 is an orally active, selective MDM2-p53 inhibitor with an IC₅₀ of 4 nM. BI-0252 can induce tumor regressions in all animals of a mouse SJSA-1 xenograft, with concomitant induction of the tumor protein p53 (TP53) target genes and markers of apoptosis.

Name
Email *

	Sorry, but the email address you supplied was invalid.